Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on… Read More
More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016 NORTH CHICAGO, IL – AbbVie (NYSE: ABBV) announced the… Read More
Vancouver, BC – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin for Injection) for pain, announced that the U.S. Food and Drug Administration (FDA) has… Read More
SECAUCUS, NJ and TORONTO, ON – Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35… Read More
First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results, showing 36 percent reduction in risk… Read More
